Increasing Folate Status of a General Population(FOLSUPP STUDY)
Effects Of A Mixed Diet Intervention Versus Folic Acid Supplementation And Metafolin® Supplementation On Folate Status And Cardiovascular Disease Risk Factors In Healthy Adults
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Norfolk
-
Norwich, Norfolk, United Kingdom, NR4 7UA
- Institute of Food Research
-
-
Yorkshire
-
Sheffield, Yorkshire, United Kingdom, S10 2FN
- University of Sheffield
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men and women aged 18-65 years
- Smokers and non-smokers
Exclusion Criteria:
- Pregnant or has been pregnant within the last 12 months
- Breastfeeding
- Has donated or intends to donate blood within 16 weeks of the first or last study samples
- Fails standard clinical screening of blood and urine for human studies at the Institute of Food Reseach
- BMI above 18 or below 40
- Receiving vascular disease or anti-hypertensive drugs
- Those with diabetes
- Regularly consuming dietary supplements containing B-vitamins and/or folic acid.
[As the capsules are prepared from gelatin, true vegetarians may not wish to participate]
Study Plan
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
|
Placebo
|
|
Experimental: Diet
200 µg folate per day from folate-rich foods
|
200 µg folate per day from folate-rich foods
|
|
Experimental: Folic acid supplement
200 µg folate per day from supplemental folic acid
|
200 µg folate per day from supplemental folic acid
|
|
Experimental: Metfolin supplement
200 µg folate per day from supplemental Metafolin®
|
200 µg folate per day from supplemental Metafolin®
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Folate status
Time Frame: Baseline and 16 weeks
|
Baseline and 16 weeks
|
|
Homocysteine status
Time Frame: Baseline and 16 weeks
|
Baseline and 16 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Cardio vascular disease markers
Time Frame: Baseline and 16 weeks
|
Baseline and 16 weeks
|
|
Inflammatory markers
Time Frame: Baseline and 16 weeks
|
Baseline and 16 weeks
|
|
Pulse wave velocity
Time Frame: Baseline and 16 weeks
|
Baseline and 16 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Paul M Flingas, BSc, Quadram Institute Bioscience
- Principal Investigator: Hilary Powers, BSc PhD, University of Sheffield
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- IFR001/2005
- NORFOLK LREC 05/Q0101/51
- FSA GRANT NUMBER N05057
- IFR PROJECT NUMBER 51943F
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.